Monoclonal antibodies that target PD-1, PD-L1, and CTLA-4 confer significant and often durable clinical responses and have set new standards of care across a variety of malignant diseases (especially melanoma and lung cancers) [2–4]. Here, CD274 is linked to melanoma.